Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in an upcoming investor conference.
Management will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 11:20 am ET. The virtual event will be accessible via webcast on the company's investor relations website.
Rapport Therapeutics (NASDAQ:RAPP), una società biotecnologica in fase clinica focalizzata sullo sviluppo di farmaci di precisione a base di piccole molecole per disturbi neurologici e psichiatrici, ha annunciato la sua partecipazione a una prossima conferenza per investitori. La Direzione parteciperà a una fireside chat al TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit il 17 settembre 2025 alle 11:20 ( ora orientale ). L'evento virtuale sarà accessibile tramite webcast sul sito di relazioni con gli investitori dell'azienda.
Rapport Therapeutics (NASDAQ:RAPP), una empresa de biotecnología en etapa clínica centrada en desarrollar fármacos de precisión a base de moléculas pequeñas para trastornos neurológicos y psiquiátricos, ha anunciado su participación en una próxima conferencia para inversores. La dirección participará en una charla informal (fireside chat) en TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit el 17 de septiembre de 2025 a las 11:20 a.m. hora del Este. El evento virtual será accesible mediante webcast en el sitio web de relaciones con inversores de la empresa.
Rapport Therapeutics (NASDAQ:RAPP), 신경학 및 정신 질환을 위한 소분자 정밀 의약품 개발에 중점을 둔 임상 1상 생명공학 기업으로, 다가오는 투자자 컨퍼런스 참여를 발표했습니다. 경영진은 TD Cowen의 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit에서 2025년 9월 17일 동부 표준시 11:20에 fireside chat에 참여할 예정입니다. 이 가상 행사는 회사의 투자자 관계 웹사이트에서 웹캐스트를 통해 접속 가능합니다.
Rapport Therapeutics (NASDAQ:RAPP), une société de biotechnologie en stade clinique axée sur le développement de médicaments de précision à base de petites molécules pour les troubles neurologiques et psychiatriques, a annoncé sa participation à une prochaine conférence pour investisseurs. La direction participera à une fireside chat lors du TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit le 17 septembre 2025 à 11h20, heure de l'Est. L'événement virtuel sera accessible via webcast sur le site des relations investisseurs de l'entreprise.
Rapport Therapeutics (NASDAQ:RAPP), ein klinisch orientiertes Biotech-Unternehmen, das sich auf die Entwicklung von Small-Molecule-Precision-Medicines für neurologische und psychiatrische Erkrankungen konzentriert, hat seine Teilnahme an einer bevorstehenden Investorenkonferenz angekündigt. Die Geschäftsführung wird an einer Fireside-Chat-Sitzung bei der TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit am 17. September 2025 um 11:20 Uhr Eastern Time teilnehmen. Die virtuelle Veranstaltung ist über den Webcast auf der Website des Investor-Relations-Portals des Unternehmens zugänglich.
Rapport Therapeutics (NASDAQ:RAPP)، شركة تكنولوجيا حيوية في مرحلة التجارب السريرية تركز على تطوير أدوية دقيقة تعتمد على جزيئات صغيرة للاضطرابات العصبية والنفسية، أعلنت عن مشاركتها في مؤتمر للمستثمرين. ستشارك الإدارة في جلسة fireside chat في TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit في 17 سبتمبر 2025 الساعة 11:20 صباحاً بتوقيت شرق الولايات المتحدة. الحدث الافتراضي سيكون متاحاً عبر البث المباشر على موقع علاقات المستثمرين بالشركة.
Rapport Therapeutics（NASDAQ:RAPP），一家处于临床阶段的生物技术公司，专注于开发用于神经疾病和精神疾病的小分子精准药物，宣布将参加即将举行的投资者大会。管理层将于2025年9月17日美国东部时间11:20参加TD Cowen的第五届神经精神病学与癫痫新机制峰会的炉边谈话。该虚拟活动将通过公司投资者关系网站的网络广播提供。
- None.
- None.
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference.
TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (virtual) – fireside chat on Wednesday, September 17, 2025, at 11:20 am ET.
Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
When is Rapport Therapeutics (RAPP) presenting at TD Cowen's Neuropsychiatry Summit?
How can investors access Rapport Therapeutics' (RAPP) presentation at the TD Cowen Summit?
What type of medicines does Rapport Therapeutics (RAPP) develop?
Is Rapport Therapeutics' (RAPP) presentation at TD Cowen's Summit in-person or virtual?
